Dazodalibep
Sponsors
Amgen
Conditions
Sjogren's SyndromeSjögren's SyndromeSjögren's Syndrome (SS)
Phase 3
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
CompletedNCT06104124
Start: 2024-01-24End: 2026-08-17Updated: 2026-09-14
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
Active, not recruitingNCT06245408
Start: 2024-04-08End: 2026-12-17Updated: 2026-01-08
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
RecruitingNCT06747949
Start: 2025-02-25End: 2029-12-11Target: 844Updated: 2026-04-28